Purchase Order 75N91020P00469

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for $11,484.18 on August 12, 2019, for sequencing services. Work is performed in Piscataway, New Jersey. The order carries a firm fixed price and is scheduled for completion by September 11, 2019.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for $3,567.96 on August 11, 2017, for peptide services. Work is performed at the awardee's facility in Piscataway, New Jersey. The order is firm fixed price and carries a completion date of September 30, 2017.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for $3,666.96 on June 28, 2017. Performance occurs in Piscataway, New Jersey. The order procures peptide services on a firm fixed price basis, with ultimate completion targeted for July 27, 2017.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for $11,663.10 on May 28, 2019, to procure custom gene synthesis, custom peptide synthesis, direct cloning, and plasmid services. Work is performed in Piscataway, New Jersey. The order is firm fixed price with an ultimate completion date of June 27, 2019.</p>

The National Cancer Institute awarded a $17,064.17 firm fixed price contract to Genscript USA Inc. under a Blanket Purchase Agreement (BPA) call for the production of three custom antibodies and associated proteins required for antibody production. The award was made on November 18, 2019, with an ultimate completion date of January 3, 2025. The contract was processed to de-obligate expiring FY20 funding lines in accordance with NIH Office of Administrative Law and Management (OALM) Communication...

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for peptide services valued at $7,701.00 on July 11, 2017. Place of performance is Piscataway, New Jersey. The order is firm fixed price with an ultimate completion date of August 9, 2017.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. valued at $3,964.20 on September 5, 2017, for peptide services. Work is performed in Piscataway, New Jersey. The order carries a firm fixed price structure and ultimate completion date of October 5, 2017.</p>

<p>The National Cancer Institute awarded a purchase order to GenScript USA Inc. for $6,126.56 on July 28, 2017, for sequencing services. Work is performed in Piscataway, New Jersey. The order is firm fixed price with an ultimate completion date of September 30, 2017.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for $12,098.14 on May 5, 2021, for custom gene synthesis, custom peptide synthesis, direct cloning, plasmid preparation, and crude peptide library services. The order carries no small business set-aside. Work is performed in Piscataway, New Jersey, with an ultimate completion date of June 15, 2021.</p>

Genscript USA Inc. has been awarded a firm fixed price purchase order valued at twelve thousand fifty-four dollars and fifty cents ($12,054.50) by the National Institutes of Health's National Cancer Institute to conduct research in antibody engineering using DNA. The work will be performed in Piscataway, New Jersey through March 31st, 2024. No set-aside designation was applied to this contract for antibody engineering with DNA awarded by the Department of Health and Human Services agency to...